Welcome to our dedicated page for Argenx Se news (Ticker: ARGX), a resource for investors and traders seeking the latest updates and insights on Argenx Se stock.
argenx SE reports developments as a global immunology company developing and commercializing antibody-based medicines for severe autoimmune diseases. Its updates center on VYVGART (efgartigimod alfa-fcab) and VYVGART Hytrulo (efgartigimod alfa and hyaluronidase-qvfc), including approved use in adult generalized myasthenia gravis and clinical and regulatory work across myasthenia gravis and chronic inflammatory demyelinating polyneuropathy.
Recurring announcements also cover product sales, business updates, presentations of neuromuscular data, and pipeline progress for candidates such as empasiprubart, a monoclonal antibody targeting complement factor C2, and adimanebart. Governance items include annual general meeting results, board appointments, and leadership transitions for the Euronext- and Nasdaq-listed foreign issuer.
argenx (ARGX) entered a definitive agreement to acquire Forte Biosciences (FBRX) for $77 per share in cash, implying an equity value of approximately $2.2 billion. The price reflects an about 86% premium to Forte’s volume-weighted average price since its July 9, 2026 Phase 1b vitiligo data.
Through a wholly owned subsidiary, argenx will launch a cash tender offer for all outstanding Forte shares, followed by a back-end merger at the same price. The deal, funded entirely from cash on hand, is not subject to a financing condition and is expected to close in Q3 2026, subject to customary conditions including majority tender and Hart-Scott-Rodino clearance. The transaction adds Forte’s lead asset FB102, a first-in-class anti-CD122 antibody with Phase 1b data in vitiligo and celiac disease and potential additional autoimmune indications, to argenx’s immunology pipeline.
argenx (Euronext & Nasdaq: ARGX) reported strong half year 2026 results, driven by VYVGART growth. Second quarter 2026 product net sales reached $1.5 billion, up 60% year-over-year and 17% quarter-over-quarter, contributing to $2.8 billion product net sales for the first six months.
Total operating income was $1.5 billion for Q2 and $2.9 billion for H1 2026, with operating profit of $494 million in Q2 and $887 million in H1. Profit for the period rose to $472 million in Q2 and $838 million in H1, compared to $245 million and $415 million in 2025.
argenx expanded the U.S. label for VYVGART and VYVGART Hytrulo to cover all generalized myasthenia gravis serotypes and advanced multiple registrational studies across myositis, MMN, ITP, Sjogren’s disease and Graves’ disease. Cash, cash equivalents and current financial assets totaled $5.2 billion at June 30, 2026, supporting its Vision 2030 pipeline and commercial plans.
argenx (Euronext & Nasdaq: ARGX) will host a conference call and audio webcast on Thursday, July 23, 2026 at 2:30 p.m. CET (8:30 a.m. ET) to discuss its half year 2026 financial results and provide a second quarter business update. Investors can access the live webcast and a replay, available for about one year, via the Investors section of the argenx website or join by phone using access code 3810049 and the listed country-specific dial-in numbers.
argenx (NASDAQ:ARGX) will host an R&D webinar titled “R&D Spotlight: Advancing FcRn Leadership into Autoimmune Myositis” on June 23, 2026 at 2:00pm ET. The event features argenx leaders and external autoimmune myositis experts.
A live webcast and replay will be available on the argenx investor website, along with supporting presentation slides.
argenx (NASDAQ:ARGX) reported new VYVGART (efgartigimod) data in myositis and Sjogren’s disease at EULAR 2026, highlighting sustained benefit and consistent safety.
ALKIVIA+ 52‑week myositis data showed maintained Total Improvement Scores, while RHO+ Sjogren’s results indicated maintained or improved disease activity on long-term, including biweekly dosing, with a reinforced cross-indication safety profile across 834 patients and 1,300+ patient‑years.
argenx (NASDAQ:ARGX) will host a myositis-focused R&D webinar titled “R&D Spotlight: Advancing FcRn Leadership into Autoimmune Myositis” on June 23, 2026 at 2:00 p.m. ET.
The event will cover disease biology, autoantibodies, the ALKIVIA clinical program, and clinical and commercial opportunities for efgartigimod, with a live webcast and one-year replay on the argenx investor website.
argenx (NASDAQ:ARGX) announced management participation in two June 2026 investor conferences. The team will present at the William Blair 46th Annual Growth Stock Conference on June 3, 2026 at 12:40 p.m. CT in Chicago and join a fireside chat at the Goldman Sachs 47th Annual Global Healthcare Conference on June 9, 2026 at 4:00 p.m. ET in Miami.
A live webcast and 30-day replay will be available in the Investors section of the argenx website.
MindWalk Holdings (NASDAQ: HYFT) reported that over 20 drug candidates in partner pipelines originated from its antibody discovery work, with 10 programs now in active Phase 1–3 clinical trials across oncology, immunology, neurology, and infectious disease.
The company highlighted its HYFT® and LensAI™ biological intelligence infrastructure, built on a Knowledge Graph indexing 660 million biological patterns and 25 billion relationships, and a record of 400+ peer-reviewed publications and patents supporting collaborations with firms such as Annexon, argenx, Xencor, Cullinan Oncology, and others.
argenx (NASDAQ:ARGX) announced U.S. FDA approval expanding VYVGART and VYVGART Hytrulo to treat all adult gMG serotypes (anti-AChR, anti-MuSK, anti-LRP4 and triple seronegative) based on Phase 3 ADAPT SERON data, including a statistically significant primary endpoint (p=0.0068) and a 3.35‑point mean MG‑ADL improvement at week 4. The approval cites rapid, sustained symptom improvements and a tolerability profile consistent with prior data, and broadens prescribing to adults regardless of serotype. Access support is available via the My VYVGART Path program.
argenx (NASDAQ:ARGX) reported Q1 2026 results and a business update: $1.3B product net sales (+63% YoY), operating profit of $394M, profit for the period of $366M (+116% YoY), and cash and current financial assets of $4.9B as of March 31, 2026.
Key near-term catalysts include a PDUFA date for seronegative gMG on May 10, 2026, multiple upcoming topline readouts in 2026–2027, and pipeline progression toward 10 clinical candidates by end of 2026.